Sabine Vogler

Sabine Vogler
Gesundheit Österreich GmbH | GÖG · Pharmacoeconomics

Mag. rer. soc. ec., PhD

About

168
Publications
86,989
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
2,650
Citations
Introduction
Sabine Vogler is senior researcher and Head of the Pharmacoeconomics Department at Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute). She is also Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies affiliated to the Pharmacoeconomics Department. Sabine Vogler has expertise and in-depth knowledge on medicine prices and pharmaceutical policies related to pricing, reimbursement and distribution, particularly for European countries as well as cost-containment reforms, access and affordability issues.
Additional affiliations
October 1995 - present
Gesundheit Österreich GmbH
Position
  • Head of Pharmacoeconomics Department, Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies

Publications

Publications (168)
Article
In 2020, Brazil joined Pharmaceutical Pricing and Reimbursement Information (PPRI). PPRI is a network of public authorities responsible for pharmaceutical pricing and reimbursement policies from 50, mainly European, countries. It offers a platform to its members to share information and experiences regarding pricing and reimbursement policies for m...
Article
Several European countries have introduced centralised procurement for all or some medicines. This article comparatively describes key features of national centralised pharmaceutical procurement (CPP) systems of six European countries (Cyprus, Denmark, Estonia, Italy, Norway and Portugal). Additionally, it aims to identify benefits, challenges and...
Article
Full-text available
Background: Horizon scanning aims to systematically identify upcoming health technologies and thus allows policy-makers to be better prepared for the entry of new medicines with possibly high price tags into the national health system. The aim of this study is to survey the existence of national and cross-national horizon scanning systems for medic...
Article
Full-text available
Austria is a middle-sized, high-income country in Central Europe with universal health coverage and a highly fragmented health care system. Medicines for outpatient use that are reimbursed by the social health insurance are price-regulated, whereas medicines for inpatient use are neither subject to price regulation nor to health technology assessme...
Article
Objective: The study aimed to evaluate centralised procurement of medicines (CPM) in Portugal. Methods: Data were collected through different methods, including a review of the literature and (procurement) documents and an analysis of selected bids. Thirty-seven face-to-face interviews with representatives of public authorities, users (hospitals...
Chapter
Auf einen Blick Biosimilars gelten als ein vielversprechender Ansatz, um leistbaren und nachhaltigen Zugang zu biologischen Arzneimitteln zu ermöglichen. Um den Einsatz von preisgünstigeren Biosimilars zu fördern, wenden europäische Länder unterschiedliche Marktsteuerungsmechanismen an, die zum einen an den Preisen und zum anderen an der Nachfrage...
Chapter
Full-text available
Zusammenfassung Zusammenfassung Im europäischen und internationalen Vergleich ist das deutsche Preisniveau von Arzneimitteln hoch – insbesondere das von neuen patentgeschützten Medikamenten. Preisregulierungen können dazu beitragen, die nachhaltige Finanzierung des Solidarsystems zu sichern. In diesem Beitrag werden Preisregulierungen im internati...
Article
To ensure equitable access to medicines and vaccines, organizational efforts and purchase volumes have been pooled in joint procurements and negotiations for decades in some regions of the world, as well as globally through supranational procurement mechanisms. In Europe, countries started to collaborate on procurement and negotiations recently whe...
Article
This article illustrates a consensus opinion of an expert panel on the need and usefulness of a framework for price and reimbursement (P&R) process and managed entry agreements (MEAs) for orphan medicines in Italy. This opinion was gathered in three rounds: an introductory document was sent to the panel and discussed during a recorded online meeti...
Article
Full-text available
Background There are concerns that high prices of cancer medicines may limit patient access. Since information on prices for cancer medicines and their impact on affordability is lacking for several countries, particularly for lower income countries, this study surveys prices of originator cancer medicines in Europe and Latin America and assesses t...
Article
Full-text available
Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies. This article informs about different policy measures employed by Europe...
Article
Full-text available
The 4th PPRI Conference, held in Vienna in October 2019, addressed issues related to equitable and affordable access to medicines. A multi-stakeholder audience from around the globe discussed solutions and best practice models for current challenges such as high-priced medicines, limitations of current pricing and reimbursement policies and tight b...
Article
Full-text available
Background Several governments apply the policy of external price referencing (EPR), which considers the prices of a medicine in one or more other countries for the purpose of setting the price in the own country. Different methodological choices can be taken to design EPR. The study aimed to analyse whether, or not, and how changes in the methodol...
Article
Full-text available
Background and objective Little is known about how much public payers spend on orphan medicines. This study aimed at identifying information on orphan medicine expenditure incurred by public payers that was published in literature globally and at possibly synthesising their shares as portion of the total pharmaceutical expenditure. Methods A liter...
Article
Full-text available
Managed entry agreements (MEAs) have been used for several years, with the aim of curbing the growth of pharmaceutical expenditure and enhancing patient access to innovation. Yet, much remains to be understood about their economic implications. This paper studies the impact of MEAs on list prices, that is, prices before the deduction of any discoun...
Chapter
https://www.dak.de/dak/download/report-2335144.pdf
Chapter
Auf einen Blick In Biosimilars werden hohe Erwartungen hinsichtlich ihres Einsparpotenzials gesetzt. Um den Einsatz von Biosimilars zu fördern, wenden europäische Länder verschiedene Marktsteuerungsmaßnahmen an. Ein Vergleich mit 15 europäischen Ländern zeigt hierbei meist ähnliche Zugänge bei den analysierten Ländern und auch im Vergleich zu Deuts...
Article
Shortages of medicines have become a major public health challenge. The aim of this study was to survey national measures to manage and combat these shortages. A questionnaire survey was conducted with public authorities involved in the Pharmaceutical Pricing and Reimbursement Information (PPRI) network. Reponses relating to measures as of March /...
Article
Background Several countries have seen an increase in medicines shortages that constitute a major public health threat as they can negatively impact the health outcomes of patients. The study aims to survey measures that European countries apply or consider introducing to address medicines shortages. Methods A questionnaire was sent to the public...
Technical Report
This report assesses five government-led, voluntary cross-country collaborations in the WHO European Region that aim to improve access to essential medicines through joint activities: the Baltic Procurement Initiative, Beneluxa Initiative, Fair and Affordable Pricing, Nordic Pharmaceutical Forum and Valletta Declaration. These cover activities incl...
Chapter
Medicine price regulation aims to contribute to more affordable access to medicines for both patients and public payers. While there is strong evidence for its achievements, high prices remain a barrier to access, increasingly also in high-income countries. This chapter discusses existing medicine pricing policies, particularly for new medicines, s...
Preprint
Full-text available
Background: Several governments apply the policy of external price referencing (EPR), which considers the prices of a medicine in one or more other countries for the purpose of setting the price in the own country. Different methodological choices can be taken to design the EPR policy. The study aimed to analyse whether, or not, and how changes in...
Preprint
Full-text available
Background: Several governments apply the policy of external price referencing (EPR), which considers the prices of a medicine in one or more other countries for the purpose of setting the price in the own country. Different methodological choices can be taken to design EPR. The study aimed to analyse whether, or not, and how changes in the methodo...
Technical Report
Full-text available
The study “Medicine shortages: international evidence and recommendations” informs about the extent of shortages, their causes and possible measures. The situation with regard to medicine shortages and actions taken to manage, reduce and prevent shortages in four European countries (Finland, Italy, the Netherlands and Sweden) is presented as case s...
Article
Questo contributo si propone come commento al documento “Prezzo, rimborso e accesso ai farmaci in Italia: le proposte di riforma di quattro panel di esperti“ (in questo stesso numero di Politiche sanitarie, pp. 168-179), che sintetizza i risultati del lavoro di un gruppo di esperti articolato in quattro panel nell’ambito di un seminario residenzial...
Technical Report
Full-text available
The PPRI Report 2018aims to provideinformation of currently existing pharmaceutical pricing and reimbursement policies in the 47 PPRI member countries. https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI%20Report2018_2nd_edition_final.pdf
Article
Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies
Article
Objective The study aimed to analyse the financial burden that co-payments for prescribed and reimbursed medicines pose on patients in European countries. Methods Five medicines used in acute conditions (antibiotic, analgesic) and in chronic care (hypertension, asthma, diabetes) were selected. Co-payments (standard and five defined population grou...
Article
Full-text available
The study aimed to explore the priorities of authorities and payers related to policy options for pharmaceutical pricing and reimbursement and to understand the rationale of their preferences. Representatives of competent authorities for pharmaceutical pricing and reimbursement and public payers of the 28 EU Member States were invited to express th...
Article
Full-text available
Background: Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed to a perceived growth in OOP payments for outpatient medicines, including those covered by the benefits package scheme (the Additional Drug Package, ADP). The study aimed to exp...
Article
Objectives There is no established methodology to assess the feasibility of medicine price data sources. Against this backdrop, a framework to guide the selection of most appropriate price data sources for pharmacoeconomic research has been developed. Methods A targeted literature review was carried out. Dimensions discussed in literature as relev...
Article
Full-text available
Background There are indications of staggered market entry of medicines in the national markets, with medicines being marketed first in countries with high prices. This study aimed to analyse the availability and evolution of medicine prices in the European Union (EU). Methods This research was performed for an illustrative sample of five medicine...
Article
Background: Medicine purchasing and pricing decisions usually rely on officially published prices. Literature has reported evaluations of publicly stated prices. However, due to the frequent use of confidential price arrangements there are indications for paucity of data on actual medicine prices. Therefore, the study aimed to systematically revie...
Chapter
The chapter presents studies that investigated developments in medicine prices and/or analysed medicine price data over time in order to assess effects of policy measures, patent expiry or other events (impact assessments). A range of methods was used. Most commonly used ones include descriptive analysis, time-series analysis and regression analysi...
Chapter
External price referencing (EPR) describes a policy to set medicine prices based on price data of the same medicine in other countries. The aim of this chapter is to present how EPR was implemented in the framework of pharmaceutical pricing in European countries and on a global scale. It provides an analysis of similarities and differences in the d...
Chapter
The aim of this chapter is to provide an overview of available medicine price studies in different regions of the world. The presentation of the studies is clustered as follows: (1) generic and biosimilar medicines, (2) high-priced medicines including orphan medicinal products, (3) medicines for specific indications (e.g., HIV/AIDS, Hepatitis C), (...
Book
Medicine Price Surveys, Analyses and Comparisons establishes guidelines for the study and implementation of pharmaceutical price surveys, analyses, and comparisons. Its contributors evaluate price survey literature, discuss the accessibility and reliability of data sources, and provide a checklist and training kit on conducting price surveys, analy...
Technical Report
Full-text available
Key messages • Policy-makers and purchasers increasingly face very high price tags for new medicines, and some worry that these prices challenge the financial sustainability of solidarity- based, publicly funded health care systems. • EU Member States use a mix of policy instruments to regulate the prices and determine the reimbursement of medicine...
Technical Report
Full-text available
This report reviews and analyses different reimbursement policies for medicines applied by countries in the WHO European region. The study used a mixed methods approach including primary data collection through a questionnaire addressing the competent authorities included in the Pharmaceutical Pricing and Reimbursement Information (PPRI) network,...
Chapter
This chapter deals with challenges and possible solutions to ensure affordable patient access to high-cost medicines in Europe. In recent years, even high-income countries have been struggling to provide affordable access to new, high-cost medicines. Less affluent countries and small markets have been suffering from delayed launch and, in some case...
Article
Background: Despite potentially considerable implications for public health, the environment and public funds, medicine waste is an under-researched topic. This study aims to analyse medicines drawn from household garbage in Vienna (Austria) and to assess possible financial implications for public payers. Methods: Four pharmaceutical waste sampl...
Chapter
Full-text available
https://www.barmer.de/blob/125228/3c5d541966251406905d1b5914008b69/data/dl-5-vogler.pdf
Article
Full-text available
Introduction/Study objective: This paper aims to survey the policies implemented by European countries for pricing and promoting the use of biosimilar medicines and to explore similarities and differences with policies for generic medicines. Methods: A literature review was supplemented by primary data collection with policymakers. Members of the P...
Article
Full-text available
Objectives To study the impact of tendering for off-patent outpatient medicines in terms of savings for payers and availability of medicines, to explore stakeholder perceptions and to elaborate prerequisites for a successful implementation of the policy. Methods We selected three case studies (Belgium, Denmark and the Netherlands). Information wa...
Article
Full-text available
Affordable patient access to medicines, particularly to new premium-priced medicines, is an issue, even in high-income countries. The pharmaceutical industry has argued in favour of price discrimination amongst countries based on confidential discounts as a solution to ensuring affordability and availability in less-resourced countries. In this edi...
Article
Full-text available
Objectives: The aim of this study is to conduct an analysis on the regulation and application of managed entry agreements (MEA) for oncology drugs across different European countries. Methods: Literature search and document analysis were performed between September 2015 and June 2016 to collect information on the regulatory framework and practice o...
Article
Full-text available
Managed-Entry Agreements (MEA) kommen immer häufiger auch in Österreich zum Einsatz. Unter MEA werden verschiedene Formen von vertraulichen Abkommen zwischen Pharmaherstellern und Zahlern (Krankenanstaltenträgern, Sozialversicherungen) subsummiert, die vor allem dort ausverhandelt werden, wo über den Nutzen der Medikamente Unsicherheit besteht, abe...
Article
Full-text available
Institutional payers for pharmaceuticals worldwide appear to be increasingly negotiating confidential discounts off of the official list price of pharmaceuticals purchased in the community setting. We conducted an anonymous survey about experiences with and attitudes toward confidential discounts on patented pharmaceuticals in a sample of high-inco...
Article
Hintergrund Selbstbehandlung („Self Care“) soll dazu beitragen Patientinnen/Patienten verstärkt an der eigenen Gesundheitsbehandlung zu beteiligen und damit auch die Versorgungseffizienz zu steigern. Allerdings liegt kaum Evidenz zum vermuteten Mehrwert von Selbstbehandlungs-Maßnahmen bei minderschweren Beschwerden vor. Diese Studie führte daher ei...
Article
Full-text available
This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also con...
Chapter
This chapter provides an introductory review synthesizing the literature from 2010 to 2015 concerning various methods of health economic evaluations used in hospital- and community-based studies of pharmacy services. A review of the literature (2010-15) was performed to identify relevant, peer-reviewed articles. We provided a synthesis of the metho...
Article
Full-text available
In den meisten europäischen Ländern und verstärkt auch weltweit setzen die öffentlichen Zahler Preise von neuen Arzneimitteln anhand eines internationalen Preisvergleichs (External Price Referencing; EPR) fest. Dabei werden die Preise gleicher Arzneispezialitäten aus definierten anderen Ländern als Basis für die Preisfestlegung herangezogen. Seit ü...
Technical Report
Full-text available
This report explores the causes of high out-of-pocket (OOP) payments for outpatient medicines in Kyrgyzstan and develops policy recommendations to reduce them. The analysis consisted of a review of current reimbursement mechanisms and an assessment of their ability to protect the Kyrgyz population from high OOP payments. The analysis showed that Ky...
Book
Full-text available
In the context of pharmaceutical care, policy-makers repeatedly face the challenge of balancing patient access to effective medicines with affordability and rising costs. With the aim of guiding the health policy discourse towards questions that are important to actual and potential patients, this study investigates a broad range of regulatory meas...
Technical Report
Full-text available
Gesundheit Österreich GmbH (Austrian Public Health Institute) was commissioned by the Austrian Federal Ministry of Health and Women‘s Affairs to conduct a price survey and comparison of 60 high-cost medicines. The latter were defined as those medicines that accounted for a high share of pharmaceutical expenditure to Austrian public payers. Price da...
Technical Report
Full-text available
This study provides a comparison of prices of 60 high-cost medicines in Austria and the other Member States of the EU. The analysis showed that in comparison to other European countries Austrian prices of the surveyed medicines used in hospitals are higher than those of the selected out-patient medicines. A second key finding was that the Austrian...
Article
Full-text available
In the context of pharmaceutical care, policy-makers repeatedly face the challenge of balancing patient access to effective medicines with affordability and rising costs. With the aim of guiding the health policy discourse towards questions that are important to actual and potential patients, this study investigates a broad range of regulatory meas...
Article
Full-text available
Background: In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-income countries. Methods: We c...
Article
Objective: To review the international body of literature from 2010 to 2015 concerning methods of economic evaluations used in hospital- and community-based studies of pharmacy services in publicly funded health systems worldwide, their clinical outcomes, and economic effectiveness. Data sources: The literature search was undertaken between May...
Article
Background: Policy-makers can use a menu of pharmaceutical policy options. This study aimed to survey these measures that were implemented in European countries between 2010 and 2015. Methods: We did bi-annual surveys with competent authorities of the Pharmaceutical Pricing and Reimbursement Information network. Additionally, we consulted poster...